Find clinical trials for Lymphoma in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma

Leukemia

Non-Hodgkin Lymphoma

Lymphoid Leukemia

Diffuse Large B-Cell Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Atlanta, GA, USA:

DS-3201b in Participants With Lymphomas

DS-3201b is an experimental drug that is being investigated in clinical research.Adults with non-Hodgkin lymphoma (NHL) may be able to join ...

Active, not recruiting

Lymphoma, Malignant

Non-hodgkin Lymphoma

Drug: DS-3201b

Phase 1

•

Daiichi Sankyo

Atlanta, Georgia, United States and 20 other locations

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting

Non-Hodgkin Lymphoma

Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

•

Novartis

Atlanta, Georgia, United States and 66 other locations

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non...

Enrolling

Grade 2 Follicular Lymphoma

Marginal Zone Lymphoma

Other: Quality-of-Life Assessment

Biological: Obinutuzumab

Phase 2

•

Emory University

Atlanta, Georgia, United States

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....

Enrolling

Lymphoma, T-Cell

Diffuse Large B Cell Lymphoma

Drug: CPI-0209

Phase 1, Phase 2

•

Constellation Pharmaceuticals

Atlanta, Georgia, United States and 59 other locations

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...

Active, not recruiting

Classic Follicular Lymphoma

Diffuse Large B-Cell Lymphoma

Drug: Epcoritamab

Phase 2

•

Genmab

Atlanta, Georgia, United States and 71 other locations

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...

Active, not recruiting

Relapsed/Refractory Peripheral T-Cell Lymphoma

Adult T Cell Leukemia/Lymphoma

Drug: Valemetostat Tosylate

Phase 2

•

Daiichi Sankyo

Atlanta, Georgia, United States and 59 other locations

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling

Refractory B-Cell Non-Hodgkin Lymphoma

Relapsed B-Cell Non-Hodgkin Lymphoma

Drug: Loncastuximab Tesirine

Drug: Polatuzumab Vedotin

Phase 1

•

ADC Therapeutics

Atlanta, Georgia, United States and 39 other locations